This is the first study that demonstrated that AIMs inhibited cancer proliferation by inhibiting NF-κB activity and its downstream molecules involved in cancer proliferation, invasion, and angiogenesis in in vivo systems [13]. The gene discussed is NFKB1; the disease is cancer.